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Abstract: D-amino acid oxidase (DAAO) is a flavoenzyme that degrades D-amino acids through the process of oxidative 
deamination. DAAO regulation of D-amino acid levels has been associated with several physiological processes ranging 
from hormone secretion to synaptic transmission and cognition. Recent genetic studies have identified a mutation on 
chromosome 13 in schizophrenia patients that encodes two gene products (G30 and G72) that are associated with DAAO. 
Furthermore, DAAO expression and enzyme activity has been reported to be increased in post mortem brain tissue 
samples from patients with schizophrenia compared to healthy controls. D-serine, a D-amino acid that is regulated by 
DAAO, is a potent, endogenous co-agonist of the N-methyl-D-aspartic acid (NMDA) receptor. Because NMDA receptor 
dysfunction is thought to be involved in the positive (psychotic), negative and cognitive symptoms in schizophrenia, there 
has been much interest in developing potent and selective DAAO inhibitors for the treatment of this disease. Several 
research reports have been published that describe the synthesis and biological effects of novel, selective, small molecule 
inhibitors of DAAO. Many of these compounds have been shown, when given systemically, to increase D-serine 
concentrations in the blood and brain. However, the efficacy of these compounds in behavioral assays that measure 
antipsychotic potential and pro-cognitive effects in laboratory animals has been inconsistent. This article highlights and 
reviews research advances for DAAO inhibitors published in peer reviewed journals. 
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D-AMINO ACID OXIDASE 
  D-amino acid oxidase (DAAO) is a flavoprotein that 
catalyzes the oxidative deamination of D-amino acids. 
DAAO was first identified by Krebs in 1935 [1] and since 
this initial characterization DAAO has been studied in a 
variety species ranging from microorganisms to mammals. 
The DAAO gene has been mapped to chromosome 12q23-
24.1 in human and to 5E3-F in the mouse [2]. Several 
regions of the DAAO protein are highly conserved across 
species including amino acid residues that make up the 
catalytic site of the active center. However, there is no 
significant amino acid homology within the substrate 
binding region of DAAO which may reflect the broad 
substrate specificity of this enzyme [3]. Interestingly, DAAO 
can maintain catalytic activity as a monomer and a 
homodimer in different cell types [4,  5].  
  High levels of DAAO expression and enzyme activity are 
found in the mammalian liver, kidney, and brain although 
the expression pattern can vary between species. For 
example, humans express DAAO in both the liver and 
kidney, whereas mice express DAAO in the kidney but not 
the liver [3]. The physiological role of DAAO in the kidney 
and liver is detoxification of accumulated D-amino acids [6]. 
The cellular localization of this enzyme in peroxisomes 
allows for efficient removal of the cytotoxic by-product 
hydrogen peroxide that is produced during the oxidative 
deamination of D-amino acids [7]. The physiological role of 
DAAO in the brain is less clear. DAAO expression and   
activity has been reported to be most extensive in the 
cerebellum followed by the dorsolateral prefrontal córtex 
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hippocampus and substantia nigra [8, 9]. Verrall et al. 2007 
reported robust mRNA expression and immunoreactivity for 
DAAO in Bergmann glia and in the molecular and granule 
cell layers of the human cerebellum. In contrast to the 
cerebellum, DAAO mRNA and protein were localized to 
neurons in the prefrontal cortex, hippocampus and substantia 
nigra [10]. 
POTENTIAL THERAPEUTIC APPLICATIONS OF 
DAAO INHIBITORS 
  DAAO and the D-amino acids that this enzyme regulates 
have been implicated in a wide array of physiological 
processes. In particular D-arginine affects pathways that 
regulate arterial pressure [11], D-aspartate is an important 
regulator of hormone release [12, 13], and elevated D-
alanine content has been found in the gray matter of 
Alzheimer's patients [14]. Recently, research has focused on 
understanding the role of DAAO and D-amino acids in 
relation to psychiatric disorders such as schizophrenia. In 
particular, D-serine and glycine play an important role in 
neuronal signaling by functioning as co-agonists of the 
NMDA receptor. The NMDA receptor functions as a 
molecular coincidence detector and requires the presence of 
both agonist (glutamate) and co-agonist (D-serine, glycine, 
and/or D-alanine) for the ligand-gated ion channel to open 
[15-17]. Importantly, D-serine has been reported to be the 
predominant NMDA co-agonist in the forebrain and there is 
accumulating evidence that D-serine regulates cortical and 
hippocampal NMDA receptor activity [17-19].  
  Regulation of NMDA receptor co-agonists through the 
pharmacological manipulation of DAAO and glycine 
transporters (GlyT1) have been investigated as putative 
novel therapeutics to treat schizophrenia. Currently, typical 
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frontline of treatment for schizophrenia. These therapeutics 
are moderately effective in treating the positive symptoms of 
schizophrenia, however, they fall short of addressing the 
cognitive deficits and negative symptoms associate with this 
disease [20]. Therapeutics that modulate D-serine and other 
NMDA receptor co-agonists may better address the multiple 
symptomatic domains of schizophrenia. The NMDA 
receptor is thought to play a central role in the 
pathophysiology of schizophrenia and NMDA receptor 
dysfunction may underlie the behavioral and neurobiological 
deficits observed in this disease. Accordingly, decreasing 
NMDA receptor function by administering NMDA receptor 
antagonists such as ketamine and phencyclidine (PCP) 
produced psychotomimetic symptoms, negative symptoms 
and cognitive deficits in animals and normal human subjects 
[21-23]. NMDA receptor antagonists also reinstated 
schizophrenia-like symptoms in remitted patients and 
exacerbated psychosis in patients free of antipsychotic 
medication [24]. D-serine, as well as other endogenous co-
agonists of the NMDA receptor, are decreased in both the 
serum and cerebrospinal fluid (CSF) of patients with 
schizophrenia [25-28]. Furthermore, increasing NMDA 
receptor function by co-administration of glycine, D-serine, 
or D-alanine with atypical antipsychotics improved positive, 
negative, and cognitive symptoms, in schizophrenia patients 
when compared to antipsychotic treatment alone [29-32]. 
  Gene association studies have provided another link 
between DAAO and schizophrenia. DNA from 213 
schizophrenic patients and 241 normal individuals from 
Canada were genotyped and two overlapping gene products, 
G72 and G30, were identified in a segment from 
chromosome 13q34 that has been genetically linked to 
schizophrenia [33]. The G72 gene product was found to 
increase activity of DAAO and was subsequently termed D-
amino acid oxidase activator (DAOA) [33]. This finding 
suggests that increased D-serine metabolism resulting from 
increased DAAO activity may produce a reduction in 
NMDA receptor activity. This hypothesis was tested by 
Burnet  et al. 2008 who examined DAAO expression and 
activity in postmortem cerebellar tissue from schizophrenia 
patients and normal controls. They reported that DAAO 
activity and expression were upregulated in tissue from 
schizophrenic patients, however, the increases in expression 
and activity were not related to identified SNPs or the gene 
products G72 and G30 [34]. 
  In addition to human genetic studies, DAAO mutations 
have been studied in the mouse. ddY/DAO- mice is a 
naturally occurring mouse strain that lacks DAAO activity 
and has elevated levels of D-serine in the blood and 
cerebellum [35]. These mice also have functional changes in 
synaptic transmission including increased NMDA-mediated 
excitatory post synaptic currents and enhanced hippocampal 
long term potentiation, a molecular correlate of learning and 
memory [36, 37]. ddY/DAO- mice also show improved 
cognitive performance in the Morris water maze task
36 and 
increased occupancy of the NMDA receptor compared to 
wild type animals
38. Taken together, these finding suggest 
that DAAO inhibitors might be useful as novel therapeutics 
to treat psychiatric and cognitive disorders.  
IN VITRO PROPERTIES AND IN VIVO EFFECTS OF 
DAAO INHIBITORS  
  Given that DAAO is involved in D-serine metabolism 
and that DAAO mutant mice have elevated D-serine 
concentration in brain, several investigators have described 
the use of DAAO inhibitors on D-serine levels in plasma and 
brain [35, 36, 38]. Thus, Adage et al. 2008 [39] described the 
in vitro and in vivo properties of a single compound, 5-
methylpyrazole-3-carboxylic acid, ASO57278 (1. Fig. 1).  
No structure activity information was described however   
this compound was found to be a moderately potent               
(IC50 = 0.9M) inhibitor of human DAAO activity in vitro. 
This compound was highly selective for DAAO over the 
glycine site of the NMDA receptor, D-aspartate oxidase 
(DDO) and D-serine racemase, with negligible inhibitory 
activity at these proteins up to 100M. Pharmacokinetic 
studies of ASO57278 in rat showed it to have an intravenous 
half life of 5.6 h and low clearance. The compound is orally 
bioavailable (F=41%) with a terminal half life of 7.2 h and a 
Tmax of 1 h. Furthermore, the compound is brain penetrant 
as brain and CSF concentrations were increased following 
intravenous administration, although the brain to plasma and 
CSF to plasma ratios were relatively low at 1 h (0.052 and 
0.018 respectively). AS057278 had a small but significant 
effect on D-serine relative to total serine (D-serine + L-
serine) in the cortex and midbrain after i.v. dosing of 10 
mg/kg AS057278. It is worth noting, however, that plasma 
levels achieved with this route and dose appeared to produce 
much higher drug levels than were achieved in their 
behavioral studies, which are described below.  
Duplantier  et al. 2009 described the structure activity 
relationship and pharmacokinetics of 3-hydroxyquinolin-2-
(1H)-one (2, Fig. 1) and its analogs as novel, selective and 
highly potent DAAO inhibitors [40]. Although 3-
hydroxyquinolin-2-(1H)-one is a very potent DAAO 
inhibitor (IC50 = 4nM) it also has weak affinity for the 
glycine site of the NMDA receptor (29% inhibition at 10μM) 
and some affinity for DDO (IC50 = 855nM). Pharmacokinetic 
studies in rat revealed this compound to have moderate 
clearance (46mg/min/kg) and poor oral bioavailability 
(F=0.9%), but when administered subcutaneously at 56 
mg/kg it increased cerebellar D-serine concentration and 
revealed a brain/plasma ratio of 0.7. Substitution of this 
compound with fluoro and chloro at positions 6 and 5 
respectively and replacement of the 8 carbon atom with 
nitrogen culminated in an optimized compound (3, Fig. 1) 
that had improved oral bioavailability and maintained high 
affinity for rat and human DAAO (IC50 = 4nM), and weak 
affinity IC50 >14.5M for DDO with negligible activity at 
the glycine / NMDA site. Subcutaneous administration of (3) 
in mice dose dependently increased cerebellar D-serine 
concentration 2-6 fold above control values 4 h after dosing 
although it is not clear if this increase of brain D-serine is 
due to central and / or peripheral DAAO inhibition.  
 Sparey  et al. 2008 [41] described a two fused pyrrole 
carboxylic acid (4, Fig. 1) as a moderately potent inhibitor of 
human (IC50 = 145nM) and rat (IC50 = 112nM) DAAO in 
vitro with good selectivity over human DDO. The properties 
of (4) were further described by Smith et al. 2009 to have 
good rat pharmacokinetics including oral bioavailability and 
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DAAO activity with an associated increase of plasma D-
serine [42]. However, doses of (4) that inhibited DAAO 
activity in kidney by ~80% and in brain by ~65% failed to 
markedly increase cortical levels of D-serine.  
  Interestingly, a feature of compound 4 and several other 
DAAO inhibitors is the relatively small molecular weight 
and general lack of tolerability, in terms of maintaining high 
affinity, for large group substitutions. In keeping with the 
tolerance for small molecular weight compounds, X-ray 
crystallography studies indicated that the active site in 
DAAO is small and fairly restricted [40, 41], perhaps 
consistent with the physiological role of the enzyme to 
metabolize small molecular weight amino acids. 
 Ferraris  et al. 2008 described a series of compounds 
based on a benzo[d]isoxazol-3-ol core structure as 
moderately potent, competitive (with respect to D-serine) 
inhibitors of DAAO [43]. Selectivity over DDO,           
glycine/NMDA or other receptors was not reported. 
Substitution of the core structure with larger groups (OMe, 
OEt, CF3) was generally poorly tolerated in terms of affinity 
for DAAO but smaller groups (fluoro, chloro, methyl) at 
positions 5 or 6 moderately improved DAAO affinity. The 
most potent analog described in this series was the 6-chloro 
analog (CBIO) which inhibited DAAO activity with an       
IC50 = 188nM (5, Fig. 1). Selectivity over other receptors and 
enzymes was not reported. While there are no reported 
pharmacokinetic or brain penetration studies of this 
compound, oral administration of CBIO to rats (30 mg/kg) 
increased plasma D-serine concentration similar to that 
produced by D-serine (30 mg/kg). Nevertheless, this dose of 
CBIO failed to increase extracellular cortical D-serine 
concentrations when administered alone and a similar lack of 
effect of CBIO on rat brain D-serine was found by 
Hashimoto et al. 2009 [43, 44].  
  Collectively, the limited experience with a small number 
of structurally diverse inhibitors indicates that extensive 
inhibition of peripheral and central DAAO has a limited 
effect on brain or extracellular D-serine concentration. This 
could be due to several reasons. High affinity D-amino acid 
reuptake sites could keep extracellular D-serine 
concentrations low even when DAAO activity is inhibited. 
Regional differences in the activity of brain DAAO could be 
a source of error in assessing the efficacy of inhibitors 
(cortex has very low DAAO activity compared with 
cerebellum). Poor brain penetration or lack of interaction of 
the inhibitor with the enzyme in situ. In this regard, the paper 
by Duplantier et al 2009, indicated that free compound in 
brain may need to be several-fold greater than the in vitro 
IC50 before significant elevations in D-serine are observed, at 
least in the cerebellum which has a high level of DAAO 
activity [40]. 
EFFECT OF DAAO INHIBITORS ON BEHAVIORS 
RELEVANT TO SCHIZOPHRENIA 
  When co-administered with antipsychotics, D-serine, as 
well as direct administration of other co-agonists of the 
NMDA receptor, has been reported to have therapeutic 
effects in patients with schizophrenia [29 – 32]. For this 
reason, several reports have investigated the effects of D-
serine administration in preclinical models and have 
demonstrated effects in assays predictive of clinical utility 
for positive symptoms [42, 45, 46] negative symptoms [21] 
and cognitiom [42, 47, 48]. 
  In contrast to the fairly robust effects reported with D-
serine administration, the reported behavioral effects of 
DAAO inhibitors are fairly modest and inconsistent. For 
example, we found that D-serine attenuated the psychomotor 
activating and dopamine releasing effects of amphetamine 
and reversed an MK-801 induced deficit in novel object 
recognition. In contrast, compound (4) did not produce 
behavioral or neurochemical changes in these assays. In 
addition, we have hitherto unpublished data showing that D-
serine improves recognition in a time-dependent forgetting 
protocol to assess novel object recognition, whereas 
compound (4) does not (Fig. 2). Importantly, we found that 
the dose of D-serine required for improvement in novel 
object recognition and attenuation of amphetamine-induced 
psychomotor activity elevated CSF D-serine 40-fold over 
that achieved by the maximum dose of compound (4) tested 
(200 mg/kg). These findings suggest that the increase in D-
serine needed for these behavioral effects is much greater 
than can be achieved by DAAO inhibition, at least by a 
single dose of compound (4). Administration of the DAAO 
inhibitor CBIO on its own also reportedly failed to reverse a 
prepulse inhibition (PPI) deficit induced by MK-801 
administration whereas D-serine was effective [44].  
  In contrast to the negative results described above, Adage 
et al., 2008 found that acute administration of 80 mg/kg 
AS057278 reversed a PCP-induced deficit in PPI, although 
the effect was not observed with other doses, including lower 
(40 mg/kg) or slightly higher (100 mg/kg) doses of 
AS057278. These authors also report that chronic (28 days, 
b.i.d.) administration of AS057278 reversed a PCP-induced 
deficit in PPI, but again the dose-effect curve followed a 
steep inverted U-shaped dose-effect function (10 and 40 
mg/kg were ineffective, whereas 20 mg/kg was effective). 
Finally, these authors reported that subchronic, but not acute 
administration of AS057278 attenuated the psychomotor 
activating effects of PCP. Unfortunately, no measurement of 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Chemical structures of novel DAAO inhibitors.  (1) 
ASO57278 [39], Pfizer compounds  (2)  and (3) [40], Merck 
compound (4) [42], and (5) CBIO from MGI Pharma [43].  
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brain D-serine was made after chronic dosing to determine if 
the more pronounced behavioral effects of AS057278 
following chronic dosing were due to elevated D-serine.  
  Given the moderate efficacy of DAAO inhibitors on 
brain D-serine and behavior, several authors have 
investigated the effects of co-administering DAAO inhibitors 
with D-serine on brain neurochemistry and behavioral 
assays. Indeed, Ferrais et al, 2008 showed that CBIO had 
quite pronounced effects on brain (and plasma) D-serine 
when co-administered with 30 mg/kg D-serine, relative to 
when either CBIO or D-serine was administered alone. 
Hashimoto  et al, 2009 extended this finding by showing 
effects on cortical D-serine and also demonstrated that co-
administration of D-serine (30 mg/kg) and CBIO reversed an 
MK-801-induced deficit in PPI whereas the 30 mg/kg dose 
of D-serine had no effect on its own. We have likewise 
shown that co-administration of compound (4) with D-serine 
elevates CSF and cortical D-serine to a greater extent than 
administration of D-serine alone in male rats (Fig. 3). 
Unfortunately it is not known whether the effects of CBIO or 
compound (4) on elevating D-serine levels following D-
serine administration are due to inhibition of DAAO in the 
periphery, brain or most likely both compartments. Neither is 
it clear from any of these studies whether or not such 
interactions are synergistic or additive and more extensive 
isobolargraphic analyses would be required to define the 
interaction. Nevertheless, these findings suggest that DAAO 
inhibitors could be useful clinically for reducing the dose of 
D-serine necessary to improve psychosis or cognitive 
deficits associated with schizophrenia. As a result, the co-
administration of DAAO inhibitors with D-serine could 
ameliorate some of the side effects associated with the 
administration of high doses of D-serine, such as 
nephrotoxicity [49].   
OTHER THERAPEUTIC INDICATIONS FOR DAAO 
INHIBITORS 
  Beyond its hypothesized involvement in schizophrenia, 
there is also evidence suggesting a role of D-serine, and 
potentially DAAO, in the response to painful stimuli. 
Intracerebral administered D-serine is effective in several 
pain models [50, 51] although the effects of D-serine on pain 
responsiveness might greatly differ depending on the brain 
region where it is administered (see [52] for an example of 
potentiation of the pain response by D-serine). However, 
there is a significant amount of research showing that 
NMDA receptor antagonists might be also useful for treating 
pain [53], so the mechanism of action by which D-serine has 
reported analgesic effects is not well understood.  
  The effect of DAAO inhibition on the response to painful 
stimuli has not been well studied and the few relevant studies 
are somewhat contradictory. Ren et al, 2006 showed that 
infusion of the enzyme DAAO into the rostral anterior 
cingulate cortex reduced conditioned place avoidance 
produced by formalin injections, but had no effect on acute 
pain responses induced by formalin [54]. These results were 
interpreted to indicate that decreasing D-serine (and 
presumably other D-amino acids) in the anterior cingulate 
via upregulating DAAO produces analgesic effects, and 
might suggest a nociceptive effect of inhibiting the enzyme. 
Indeed, Wake et al (2001) showed that a mutant mouse 
lacking DAAO activity is supersensitive to formalin-induced 
nociception [37]. On the other hand, Zhao et al, 2008 
showed that this same mouse strain is less sensitive to a 
variety of painful stimuli (including formalin) and that the 
DAAO inhibitor sodium benzoate has analgesic effects in 
two chronic pain assays [55]. These inconsistent findings 
highlight the need for more studies to address the potential of 
DAAO inhibitors for treating pain. Nevertheless, Sepracor 
has revealed that they plan on evaluating the effects of their 
DAAO inhibitor SEP-227900 for neuropathic pain. 
CONCLUSIONS 
 
 
 
 
 
 
 
 
 
Fig. (2). The influence of D-serine and compound 4 on novel object recognition. Groups of male Wistar Hannover rats were given D-serine 
(s.c.) or compound 4 (i.p.) and 4 hours later were placed in test cages and allowed to explore two identical objects for 90 seconds. 24 hours 
later these animals were placed back in the test cage and allowed to explore one object they had explored previously and one novel object. 
Memory for the previously encountered object is indicated by greater exploration of the novel object. The group given 1.28 g/kg d-serine 
showed greater object recognition than the vehicle treated animals, as well as greater than chance levels of exploration of the novel object. In 
contrast, none of the doses of compound 4 increased recognition. * indicates significantly greater % exploration of the novel object, relative 
to 0 mg/kg.  indicates greater than chance (50%) levels of exploration of the novel object.  D-Amino Acid Oxidase (DAAO) Inhibitors  The Open Medicinal Chemistry Journal, 2010, Volume 4    7 
  The therapeutic potential of DAAO inhibitors is 
relatively unexplored and studies have primarily addressed 
their value for pharmacotherapy in the treatment of positive, 
negative and cognitive symptoms of schizophrenia. 
However, the few published studies characterizing novel 
DAAO inhibitors have yielded conflicting results. This may 
be for several reasons including the use of DAAO inhibitors 
with different properties including potency and 
pharmacokinetics. Relatively few of the published studies 
have related efficacy (or lack thereof) to the extent of 
peripheral / brain DAAO inhibition or have demonstrated an 
increase of brain extracellular D-serine following a 
behaviorally effective dose of an inhibitor. Furthermore, the 
relative contributions of peripheral D-serine which can be 
actively transported into the brain are poorly understood. 
Interestingly, preclinical studies have provided data that 
combining a DAAO inhibitor with D-serine may be more 
effective in terms of antipsychotic like activity, however, a 
clinically acceptable strategy for this combination remains to 
be determined. 
ABBREVIATIONS 
DAAO  =  D-amino acid oxidase  
NMDA =  N-methyl-D-aspartate 
PCP =  Phencyclidine 
DAOA  =  D-Amino acid oxidase activator 
DDD =  O-aspartate  oxidase 
PPI  =  Prepulse inhibition  
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